USD 150.31
(0.94%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 3.06 Billion USD | 6.27% |
2022 | 2.88 Billion USD | 4.83% |
2021 | 2.75 Billion USD | 20.41% |
2020 | 2.28 Billion USD | 10.27% |
2019 | 2.07 Billion USD | 10.31% |
2018 | 1.88 Billion USD | 9.04% |
2017 | 1.72 Billion USD | 23.48% |
2016 | 1.39 Billion USD | 30.56% |
2015 | 1.07 Billion USD | 10.42% |
2014 | 969 Million USD | 18.17% |
2013 | 820 Million USD | -1.2% |
2012 | 830 Million USD | 31.33% |
2011 | 632 Million USD | 120.21% |
2010 | 287 Million USD | 33.49% |
2009 | 215 Million USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 906 Million USD | 13.11% |
2024 Q1 | 801 Million USD | 12.98% |
2024 Q3 | 955 Million USD | 1.55% |
2023 Q2 | 871 Million USD | 11.52% |
2023 FY | 3.06 Billion USD | 6.27% |
2023 Q1 | 781 Million USD | 19.05% |
2023 Q3 | 836 Million USD | -4.02% |
2023 Q4 | 709 Million USD | -15.19% |
2022 Q1 | 793 Million USD | 41.35% |
2022 FY | 2.88 Billion USD | 4.83% |
2022 Q4 | 656 Million USD | -11.11% |
2022 Q3 | 738 Million USD | 1.65% |
2022 Q2 | 726 Million USD | -8.45% |
2021 Q4 | 561 Million USD | -22.94% |
2021 Q2 | 724 Million USD | -4.11% |
2021 FY | 2.75 Billion USD | 20.41% |
2021 Q3 | 728 Million USD | 0.55% |
2021 Q1 | 755 Million USD | 47.17% |
2020 Q4 | 513 Million USD | -22.74% |
2020 FY | 2.28 Billion USD | 10.27% |
2020 Q1 | 539 Million USD | 7.8% |
2020 Q2 | 553 Million USD | 2.6% |
2020 Q3 | 664 Million USD | 20.07% |
2019 Q1 | 428 Million USD | -1.83% |
2019 Q4 | 500 Million USD | -11.35% |
2019 FY | 2.07 Billion USD | 10.31% |
2019 Q3 | 564 Million USD | 7.22% |
2019 Q2 | 526 Million USD | 22.9% |
2018 Q2 | 484 Million USD | 4.99% |
2018 Q1 | 461 Million USD | -9.43% |
2018 FY | 1.88 Billion USD | 9.04% |
2018 Q4 | 436 Million USD | -12.8% |
2018 Q3 | 500 Million USD | 3.31% |
2017 Q3 | 422 Million USD | 9.9% |
2017 Q1 | 367 Million USD | 15.05% |
2017 FY | 1.72 Billion USD | 23.48% |
2017 Q4 | 509 Million USD | 20.62% |
2017 Q2 | 384 Million USD | 4.63% |
2016 Q3 | 375 Million USD | 5.34% |
2016 FY | 1.39 Billion USD | 30.56% |
2016 Q1 | 347 Million USD | 52.19% |
2016 Q2 | 356 Million USD | 2.59% |
2016 Q4 | 319 Million USD | -14.93% |
2015 FY | 1.07 Billion USD | 10.42% |
2015 Q4 | 228 Million USD | -27.16% |
2015 Q3 | 313 Million USD | 15.93% |
2015 Q2 | 270 Million USD | 4.25% |
2015 Q1 | 259 Million USD | 33.51% |
2014 FY | 969 Million USD | 18.17% |
2014 Q4 | 194 Million USD | -28.94% |
2014 Q3 | 273 Million USD | 12.81% |
2014 Q1 | 260 Million USD | 34.02% |
2014 Q2 | 242 Million USD | -6.92% |
2013 Q1 | 226 Million USD | 47.71% |
2013 Q2 | 189 Million USD | -16.37% |
2013 Q3 | 211 Million USD | 11.64% |
2013 Q4 | 194 Million USD | -8.06% |
2013 FY | 820 Million USD | -1.2% |
2012 Q4 | 153 Million USD | -28.84% |
2012 Q3 | 215 Million USD | -18.56% |
2012 FY | 830 Million USD | 31.33% |
2012 Q2 | 264 Million USD | 33.33% |
2012 Q1 | 198 Million USD | 37.5% |
2011 FY | 632 Million USD | 120.21% |
2011 Q1 | 150 Million USD | 0.0% |
2011 Q2 | 137 Million USD | -8.67% |
2011 Q3 | 201 Million USD | 46.72% |
2011 Q4 | 144 Million USD | -28.36% |
2010 FY | 287 Million USD | 33.49% |
2009 FY | 215 Million USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Thermo Fisher Scientific Inc. | 6.85 Billion USD | 55.256% |
Dynavax Technologies Corporation | -37.02 Million USD | 8388.322% |
Illumina, Inc. | -1.06 Billion USD | 387.091% |
IQVIA Holdings Inc. | 1.97 Billion USD | -55.235% |
Biogen Inc. | 1.29 Billion USD | -136.659% |
Iovance Biotherapeutics, Inc. | -460.55 Million USD | 766.364% |
Mettler-Toledo International Inc. | 1.08 Billion USD | -182.263% |
Sarepta Therapeutics, Inc. | -267.82 Million USD | 1245.902% |
Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 58346.347% |
Waters Corporation | 817.67 Million USD | -275.332% |
Perrigo Company plc | 151.9 Million USD | -1920.408% |
uniQure N.V. | -282.87 Million USD | 1184.947% |
Agios Pharmaceuticals, Inc. | -391.48 Million USD | 883.934% |
Amicus Therapeutics, Inc. | -73.49 Million USD | 4275.851% |
Atara Biotherapeutics, Inc. | -276 Million USD | 1211.932% |
bluebird bio, Inc. | -244.26 Million USD | 1356.438% |
Cara Therapeutics, Inc. | -121.49 Million USD | 2626.03% |
Imunon, Inc. | -21.03 Million USD | 14693.14% |
Myriad Genetics, Inc. | -123.7 Million USD | 2581.002% |
Neurocrine Biosciences, Inc. | 250.9 Million USD | -1123.196% |
Nektar Therapeutics | -137.42 Million USD | 2333.218% |
Editas Medicine, Inc. | -169.18 Million USD | 1914.033% |
Verastem, Inc. | -92.08 Million USD | 3432.827% |
Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 121.803% |
Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 6908.305% |
Heron Therapeutics, Inc. | -110.61 Million USD | 2874.488% |
Unity Biotechnology, Inc. | -44.66 Million USD | 6970.844% |
BioMarin Pharmaceutical Inc. | 194.44 Million USD | -1478.371% |
Sangamo Therapeutics, Inc. | -274 Million USD | 1220.053% |
Evolus, Inc. | -49.23 Million USD | 6333.624% |
Adicet Bio, Inc. | -152.03 Million USD | 2118.574% |
Aclaris Therapeutics, Inc. | -97.35 Million USD | 3252.316% |
Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 24.168% |
Esperion Therapeutics, Inc. | -155.56 Million USD | 2072.834% |
FibroGen, Inc. | -281.81 Million USD | 1189.012% |
Agilent Technologies, Inc. | 1.35 Billion USD | -127.333% |
OPKO Health, Inc. | -157.02 Million USD | 2054.516% |
Homology Medicines, Inc. | -48.25 Million USD | 6459.963% |
Geron Corporation | -193.94 Million USD | 1682.416% |
Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 1187.623% |
Exelixis, Inc. | 170.88 Million USD | -1695.945% |
Viking Therapeutics, Inc. | -100.82 Million USD | 3143.828% |
Anavex Life Sciences Corp. | -55.75 Million USD | 5604.34% |
Intellia Therapeutics, Inc. | -515.29 Million USD | 695.586% |
Axsome Therapeutics, Inc. | -231.82 Million USD | 1423.843% |
Abeona Therapeutics Inc. | -48.2 Million USD | 6467.22% |
Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 28.752% |
Kala Pharmaceuticals, Inc. | -39.15 Million USD | 7938.48% |
Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 967.611% |
Corcept Therapeutics Incorporated | 107.28 Million USD | -2760.685% |
Halozyme Therapeutics, Inc. | 337.57 Million USD | -809.134% |
Blueprint Medicines Corporation | -486.27 Million USD | 731.122% |
Insmed Incorporated | -709.62 Million USD | 532.481% |
TG Therapeutics, Inc. | 20.63 Million USD | -14774.231% |
Incyte Corporation | 620.52 Million USD | -394.581% |
Emergent BioSolutions Inc. | -726.4 Million USD | 522.494% |